Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of albumin-bound docetaxel injection plus bevacizumab in platinum-resistant recurrent ovarian cancer
CTR20220667Phase 2Active
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Aug 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of albumin-bound docetaxel and bevacizumab in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by CSPC ZhongQi Pharmaceutical Technology. Started Aug 2022; status: active.
02
Drugs
albumin-bound docetaxelbevacizumab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on CTR20220667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220667.